(1) Consistent with the protocols adopted by the State Board of Pharmacy by rule, as recommended by the Public Health and Pharmacy Formulary Advisory Committee, a pharmacist may test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and prescribe, dispense and administer treatment, including drug therapy, for SARS-CoV-2.
(2) When testing for SARS-CoV-2, a pharmacist may use:
(a) A screening procedure that can be safely performed by a pharmacist; and
(b) A test that:
(A) Guides the pharmacist’s clinical decision-making;
(B) Is determined by the Centers for Medicare and Medicaid Services to qualify as a waived test under the Clinical Laboratory Improvement Amendments of 1988 (P.L. 100-578, 42 U.S.C. 201 and 263a) or federal regulations adopted pursuant to the Clinical Laboratory Improvement Amendments of 1988 or is approved by the United States Food and Drug Administration; and
(C) Is approved by the board by rule for use under this section.
(3) A pharmacist may delegate to a pharmacy technician or an intern under the pharmacist’s supervision the administrative and technical tasks of performing a task described in subsection (2) of this section.
(4) The board may adopt rules as necessary to carry out this section.